Regeneron: Q4 EPS down 46%

(CercleFinance.com) - Regeneron has reported non-GAAP EPS of $12.
56 for Q4 2022, down 46% y-o-y, on revenues that fell 31% to 3.41 billion dollars, even though they rose 14% excluding REGEN-COV and Ronapreve.

For FY 2022, it announced in adjusted EPS that is down 40% to 44.98 dollars, on revenue that is up 17% excluding REGEN-COV and Ronapreve, thereby demonstrating the commercial strength and growing diversity of the business, management said.

It also pointed out that in January, the pharmaceutical company's board of directors authorized a new 3 billion dollar share buyback program, enabling it to continue to redistribute capital directly to shareholders.


Copyright (c) 2023 CercleFinance.com. All rights reserved.